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Summary To examine the suggested biological difference between Japanese and British gastric cancers,
immunohistochemistry was used to demonstrate eight markers of biological activity in a matched series of 40
Japanese and 33 British cases. There were no differences in the proportions of Japanese and British tumours
positive to epidermal growth factor, epidermal growth factor receptor, transforming growth factor alpha,
cripto or p53. A significantly greater proportion of British tumours were positive to c-erbB-2 whilst a
significantly greater proportion of Japanese tumours were positive to nm23. British tumours had a signif-
icantly greater mean proliferating cell nuclear antigen proliferation index than Japanese tumours. These
differences could be clinically significant.
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There has been a widely held belief in the West that the
superior results achieved by Japanese centres treating gastric
cancer is, at least in part, the result of a difference in
biological behaviour between Japanese and European tum-
ours. There is some evidence to substantiate this theory:
gastric cancer is the largest cancer killer in Japan, affecting a
younger age group than in the West. Proximal lesions
account for less than 10% of Japanese tumours compared
with Europe and the US where, after a documented rise in
the incidence of proximal tumours, the latter now constitute
30-40% of presenting cases (Meyers et al., 1987, Kamp-
schoer et al., 1989). Histologically, intestinal-type tumours
predominate in Japan compared with a higher proportion of
diffuse-type tumours seen in the West (Cady et al., 1989).
Stage-matched survival rates of Japanese patients are
demonstrably better than their European counterparts
(Miwa, 1979, Takayoshi et al., 1983; Takeda et al., 1992).
The aim of this study was to compare the malignant
potential of a matched series of Japanese and European
gastric cancers analysed immunohistochemically using a batt-
ery of markers representing different facets of biological
activity. The eight markers chosen were: epidermal growth
factor (EGF), the EGF receptor (EGFR), transforming
growth factor alpha (TGF-a), cripto (a novel EGF-related
growth factor), p53, c-erbB-2, the anti-metastasis factor nm23
and, finally, proliferation indices were calculated by the
method of monoclonal antibody labelling of the proliferating
cell nuclear antigen (PCNA).
Overexpression of EGF and TGF-a, particularly in com-
bination with overexpression of EGFR are associated with
poor prognosis in gastric cancer (Tahara et al., 1986;
Sugiyama et al., 1989; Yonemura et al., 1992) and probably
play a role in autocrine stimulation of deregulated neoplastic
growth (Sporn and Todaro, 1980). Cripto is a 188 amino acid
peptide, the central portion of which shares structural
homology with EGF and TGF-a (Ciccodicola et al., 1989).
Overexpression increases with tumour stage and may be a
sensitive marker of the progression of malignancy (Kuniyasu
et al., 1991, 1995). The c-erbB-2 oncogene encodes a peptide
product similar to the EGFR, the presence of which may
further contribute to autocrine positive feedback loops
(Yamamoto et al., 1986). The immunological demonstration
of the mutant p53 protein is indicative of loss of the normal
tumour suppressive function of native p53 and is thought to
be one of the earliest changes of malignant transformation,
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common to many solid tumours, in particular, gastric and
colorectal cancers (Hollstein et al., 1991). The nm23 gene
encodes a nucleoside diphosphate kinase and was first ident-
ified as having reduced expression in murine melanoma cells
in vitro (Steeg et al., 1988). Transfection of nm23 cDNA into
highly malignant cells reduces their metastatic potential
(Leone et al., 1991a). Recently, reduced expression of nm23
has been associated with greater malignant potential in
human breast (Bevilacqua et al., 1989), colorectal (Ayhan et
al., 1993) and gastric carcinomas (Nakayama et al., 1993).
PCNA is a 36 kDa nuclear protein synthesised during
S-phase of the cell cycle and subsequently shown to be an
auxiliary protein to DNA polymerase, its absence leading to
the synthesis of short, replicative intermediates and lagging
strands of DNA only (Miyachi et al., 1978, Prelich and
Stillman, 1988). Proliferation indices derived from PCNA
labelling correlate well with established methods such as
tritiated thymidine autoradiography, but are frequently
overestimates as a result of the long half-life of the PCNA
protein (Galand and Degraef, 1989, van Dierendonck et al.,
1991, Filipe et al., 1993). The method has the advantage,
however, that it may be used in routinely fixed, archive
tissues. Correlations between PCNA indices and survival
have been shown in gastric cancer (Jain et al., 1991a, Living-
stone et al., 1992) and a number of other malignancies
(Woods et al., 1990; Yu et al., 1990, 1992; del Giglio et al.,
1992; Kerin et al., 1992).
Patients and methods
Archive paraffin blocks were selected from 33 patients who
had undergone resection of a gastric cancer at the West-
minster Hospital, London during the period 1985-90 and
were compared with material from 40 age-, sex- and stage-
matched patients who had undergone similar surgery at the
University Hospital, Hiroshima during the same period. The
mean age of the Japanese patients was 64.4 years (range
26-83 years) and the British patients 66.2 years (range
35-83 years). The male-female ratio was approximately 2:1
in both groups. The series were chosen to include a com-
parable variety of tumours of differing histological subtypes
and points of origin within the stomach.
Surgical specimens at both centres were immersed in 10%
neutral formalin within 30 min of removal from the patient
and fixed for between 48 and 72 h before sectioning. It is
important for good immunohistochemistry that consistency
ofmethodology is achieved, particularly in the case ofPCNA
(Rowlands et al, 1991).Japanese and European gastc cancer
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The blocks most representative of each tumour were
selected after examination of sections stained with haemo-
toxylin and eosin and these were then used for the
immunohistochemistry.
Immunohistochemistry
A modification of the enzyme bridge (ABC) technique was
adopted throughout (Yasui et al., 1988). Sections of 4jLm of
deparaffinised tissue were immersed in methanol containing
0.03% hydrogen peroxide for 20min to block endogenous
peroxidase activity and then incubated with non-immunised
goat serum (diluted 1:20) for 30min to reduce non-specific
binding. Sections were then incubated with the following
primary antibodies: anti-p53 (NC-020, Novocastra), diluted
1:1000, overnight at 4°C; anti-EGF (Ab-3, Oncogene
Science), 1:10 overnight at 4°C; anti-EGFR (Ab-4, Oncogene
Science, 1:100, overnight at 4°C; anti TGF-o (Ab-2,
Oncogene Science), 1:20 at room temperature for 30min;
anti-cripto (Hiroshima University), 1:500 microwaved for
25 min to expose the antigenic sites; anti-nm23 (Hiroshima
University), 1:1000 at room temperature for 30min; anti-c-
erbB-2 (NC-004, Novocastra), 1:100 at room temperature for
30 min; and anti-PCNA (PC1O, Dako), 1:20, at room
temperature for 30 min. After washing, sections were exposed
to swine anti-rabbit serum or rabbit anti-mouse serum
depending on the primary antibody, followed by strep-
tavidin-peroxidase complex at a dilution of 1:400. Perox-
idase staining was performed using 30 mg of DAB in 100 ml
of Tris-buffered hydrochloric acid containing 0.001% hydro-
gen peroxide applied for 10 min followed by counterstaining
with 3% methyl green. Positive and negative controls (the
latter in which the primary antibody was replaced by non-
immune serum) were included with each run.
For every case, each antigen was assessed independently by
two observers for extent of expression (0, no immunoreac-
tivity; 1, less than 10% ofcells lightly positive; 2, 10-50% of
cells positive; 3, more than 50% of cells strongly positive).
Also recorded were the distribution of immunoreactivity
throughout the section, classified as diffuse, patchy or focal
Table I Histopathological characteristics of Japanese and British
tumours
Japanese British
n(%) n(%)
Total cases 40 33
Stage 4 disease 25(63%) 20(61%)
Location
Cardia 10(25%) 11(33%)
Body 11(28%) 8(24%)
Antrum 17(43%) 12(36%)
Lauren type
Intestinal 19(48%) 15(45%)
Diffuse 12(30%) 11(33%)
Degree ofdifferentiation
Well 8(20%) 7(21%)
Moderate 8(20%) 8(24%)
Poor/undifferentiated 24(60%) 18(55%)
and the cellular staining pattern, classified as predominantly
nuclear, membranous or cytoplasmic.
PCNA proliferation indices were derived using the
methods previously described (Jain et al., 1991a), the index
representing the mean proportion of 1000 nucleated cells
expressing the antigen, counted from eight representative
areas of the tumour.
Statistical comparisons between groups of cases were made
using the chi-square test and the Mann-Whitney U-test for
non-parametric statistics.
Results
The histopathological characteristics of the tumours from
each series are summarised in Table I. Immunoreactivity was
abolished in all negative controls and there was close agree-
ment between observers over slide interpretation. In a small
number of cases, staining for a particular antigen failed
despite repeated attempts, reducing the numbers available for
comparison for that antigen.
Immunoreactivity to PCNA and p53 was confined to the
nucleus while immunoreactivity to EGF and cripto was
entirely cytoplasmic. The expression of EGFR, TGF-o and
c-erbB-2 was predominantly membranous. The pattern of
expression of nm23 was more variable, often cytoplasmic in
well-differentiated tumours and nuclear in poorly
differentiated tumours. No difference was seen in either the
patterns or distributions of immunopositivity to any of the
markers between Japanese and British tumours.
A comparison of the absolute numbers of immunopositive
and -negative cases are shown in Table II. There was no
significant difference in the proportions of Japanese and
British tumours immunopositive to EGF, EGFR, TGF-x,
cripto or p53, However, a significantly greater proportion of
the British tumours were immunopositive to c-erbB-2 and,
conversely, a significantly lower proportion of the British
tumours were immunopositive to nm23 (P=0.01, P<0.01
respectively, x2). The graded extents of expression ofpositive
cases are shown in Figure 1. No difference was seen between
the two series for any of the antigens.
In an attempt to examine the differences in c-erbB-2 and
nm23 expression between the two populations in more detail,
cases were grouped into advanced (stage 4) disease and ear-
lier (stages 1, 2, 3) disease. In the case of c-erbB-2, the
relative predominance of positive cases amongst the British
cases was seen in both stage groupings but it was only
possible to demonstrate statistical significance in the adv-
anced case group (Figure 2), possibly as a result of the small
numbers of cases in the earlier stage group. Similarly, the
relative predominance of tumours positive to nm23 amongst
the Japanese series was seen in both stage groups but only
the difference in the advanced group reached statistical
significance (Figure 3).
The mean inter-observer variation for assessing the PCNA
index was<5% for the British series and<7% for the
Japanese series. The mean PCNA index of the Japanese cases
was 36.7 (range 15.5-61.3) and 47.7 (range 27.8-72.6) for
the British cases, a statistically significant difference (P<
0.001, Mann-Whitney U-test) (Figure 4).
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Table II Numbers (percentages) of cases immunopositive for the specified antigens
(P-values represent comparisons between Japanese and British series, chi-square).
No. (percentage) immunopositive cases
EGF EGFR TGF-o p53 c-erbB2 cripto nm23
Japanese 22/40 28/39 21/39 17/40 8/39 18/40 35/38
(55%) (72%) (54%) (42%) (21%) (45%) (92%)
British 15/26 20/33 23/32 14/33 14/26 15/33 21/33
(58%) (61%) (72%) (42%) (54%) (45%) (64%)
P(x2) NS NS NS NS 0.01 NS <0.01
NS, not significant.
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Figure 1 Extent of expression of the various antigens in Japanese and British tumours. (Legend applies to all figures). P-values
represent comparison between series, Mann-Whitney U-test.
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Figure 2 Proportions of Japanese and British tumours immunopositive to c-erbB-2 by tumour stage. P-values represent com-
parison between series, chi-square test. *, Positive; O, negative.
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Figure 3 Proportions ofJapanese and British tumours immunopositive to nm23 by tumour stage. P-values represent comparison
between series, chi-square test. *, Positive; 0, negative.
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Figure 4 PCNA indices of Japanese and British gastric cancers.
P-value represents comparison between groups, Mann-Whitney
U-test.
Discussion
What conclusions can be drawn from this study? Tumours
from the two populations showed similar distributions of
immunoreactivity to the antigens and identical cellular stain-
ing patterns, suggesting a fundamental biological identity.
Considering the peptides other than PCNA, the proportion
of immunopositive cases did not differ significantly between
the two populations in five of the seven series examined. In
particular, no difference was seen amongst the EGF group of
peptide growth factors including EGF, EGFR, TGF-a and
cripto. These peptides are strongly implicated both in the
regulation of normal mucosal turnover (Carpenter and
Cohen, 1979) as well as in the evolution of malignancy
(Tahara et al., 1986; Sugiyama et al., 1989; Yonemura et al.,
1992; Livingstone et al., 1994). The similar expression of this
group of peptides between the two populations once again
points to a biological unity. However, a significant difference
was seen in the proportion of cases immunopositive to c-
erbB-2 and nm23.
With respect to c-erbB-2, overexpression is associated with
poor prognosis in ovarian and breast cancers (Gullick et al.,
1991). In gastric cancer, Sasaki et al. (1992) found overexp-
ression to be significantly correlated with penrtoneal dissem-
ination although studies by Jain et al. (1991b) and Tateishi et
al., (1992) do not support this finding. It is likely that
co-overexpression of c-erbB-2 with EGFR, particularly in an
environment rich in EGF and TGF-x, contributes to a high
degree of malignancy (Tahara et al., 1993).
nm23 is one of a group of 'anti-metastasis factors' now
identified and so-named as reduced expression is associated
with enhanced malignancy. Metastasis is the result of a com-
plex sequence of events and, as yet, it is ill-defined at which
point nm23 may act. It is known that nm23 gene encodes
NDP kinase and may act as a transcription factor (Vinson et
al., 1989). Loss of heterozygosity of the nm23 gene has been
reported in carcinomas of breast, lung, kidney and color-
ectum (Leone et al., 1991b). In gastric cancer, reduced nm23
immunoreactivity is associated with metastases in both local
and distant lymph nodes and the liver. Furthermore, a
reduction in immunoreactivity is seen between primary
tumours and their metastases (Nakayama et al., 1993).
The remaining difference noted between the two popula-
tions was that the PCNA proliferation index of the British
tumours was significantly higher than that of the Japanese
tumours. The significance of PCNA expression remains
controversial (Hall et al., 1990). PCNA indices fail to corr-
elate with common pathological variables including the
degree of differentiation, histopathological type and site of
tumour origin within the stomach. High PCNA indices do
correlate, however, with advanced stage, lymph node metas-
tasis and poor clinical outcome in gastric cancer (Jain et al.,
1991a; Livingstone et al., 1992). There is evidence to suggest
that PCNA expression becomes deregulated during malignant
transformation which in itself may be of significance in
determining malignant potential (Hall et al., 1990).
It is most interesting that, of the three antigens demon-
strating a significant difference between the two populations,
the two antigens associated with increased malignancy were
overexpressed in the British tumours while the antigen
associated with resistance to dissemination was correspond-
ingly underexpressed by the British tumours. One criticism of
this study is that the generally less radical surgery performed
in the UK compared with Japan leads to a relative under-
staging of the British tumours. This effect would, if anything,
serve to minimise rather than exaggerate the differences seen.
Furthermore, the effect seems to be largely independent of
tumour stage (Figures 2 and 3).
It would be dangerous to extrapolate the findings of this
study to a conclusion that gastric cancers in British patients
can be expected to behave more aggressively than their
Japanese counterparts and that this explains the difference in
clinical outcome between the two countries. What this study
does show is that, while Japanese and British stomach carc-
inomas show a fundamental biological identity, important
aspects of tumour biology may vary between different patient
populations, a finding which may have far-reaching implicat-
ions for prevention and treatment of this important disease.
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